Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Cronos Group Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.54 (market cap $157.51B), while Cronos Group Inc trades at $3.11 (market cap $1.14B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 138.2× Cronos Group Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| BBVA | CRON | |
|---|---|---|
Market Cap | $157.51B | $1.14B |
Sector | Financials | Health |
52-Week High | $28.50 | $3.27 |
52-Week Low | $17.96 | $2.30 |
Dividend Yield | 3.8% | — |
Enterprise Value | — | $341.13M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35 with a bullish technical outlook, supported by moving averages and a strong ADX trend indicator. The company reported robust Q2 2026 earnings, beating EPS estimates with $0.63 actual versus $0.59 expected, driven by loan growth and a new $2.3 billion share buyback announcement. Revenue reached $39.42 billion in 2025, with net income of $10.51 billion and a rising profit margin of 26.66%.
Outlook remains positive with analyst consensus leaning buy (53.85%) and a projected revenue increase to $42.5 billion in 2026. Key risks include regulatory probes in Spain and volatile cash flow trends, but strong profitability and institutional support suggest upside potential for investors seeking European bank exposure.
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
